Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don’t know

Por Liu, Joyce, Westin, Shannon N.
Publicado no Gynecol Oncol (2016)

The European Society of Gynecologic Oncology (ESGO) 19(th) Biannual Meeting: Overview and summary of selected topics

Por Westin, Shannon N., Randall, Leslie
Publicado no Gynecol Oncol (2016)

Personalized therapy in endometrial cancer: Challenges and opportunities

Por Westin, Shannon N, Broaddus, Russell R
Publicado em 2012

Individualized Medicine in Ovarian Cancer: Are We There Yet?

Por Westin, Shannon N., Coleman, Robert L.
Publicado no Gynecol Oncol (2017)

Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report

Por Holman, Laura L., Ren, Yulan, Westin, Shannon N.
Publicado no BMC Cancer (2015)

Pushing the envelope: expanding fertility sparing treatment of endometrial cancer

Por Stewart, Katherine Ikard, Yates, Melinda S., Westin, Shannon N.
Publicado no J Gynecol Oncol (2020)

Repurposing the Pap Smear: One Step Closer to Gynecologic Cancer Screening

Por Westin, Shannon N., Mills, Gordon B., Myers, Andrea P.
Publicado em 2013

Investigational Agents in Development for the Treatment of Ovarian Cancer

Por Westin, Shannon N., Herzog, Thomas J., Coleman, Robert L.
Publicado em 2012

MICROSATELLITE INSTABILITY IN ENDOMETRIAL CANCER: NEW PURPOSE FOR AN OLD TEST

Por Kurnit, Katherine C., Westin, Shannon N., Coleman, Robert L.
Publicado no Cancer (2019)

Rapidly Changing Landscape of Fallopian Tube Carcinoma

Por Kurnit, Katherine C., Lu, Karen H., Westin, Shannon N.
Publicado no J Oncol Pract (2019)

Early Cervical Neoplasia: Advances in Screening and Treatment Modalities

Por Tierney, Brent, Westin, Shannon N., Schlumbrecht, Matthew P., Ramirez, Pedro T.
Publicado no Clin Adv Hematol Oncol (2010)

Unusual indolent behavior of leiomyosarcoma of the vagina: Is observation a viable option?

Por Khafagy, Ayatallah M., Prescott, Lauren S., Malpica, Anais, Westin, Shannon N.
Publicado no Gynecol Oncol Rep (2017)

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease

Por Dal Molin, Graziela Z, Westin, Shannon N, Coleman, Robert L
Publicado no Future Oncol (2018)

Progestin Intrauterine Device in an Adolescent With Grade 2 Endometrial Cancer

Por Brown, Alaina J., Westin, Shannon N., Broaddus, Russell R., Schmeler, Kathleen
Publicado em 2012

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Por Lakomy, David S., Urbauer, Diana L., Westin, Shannon N., Lin, Lilie L.
Publicado no Clin Transl Radiat Oncol (2019)

Clinical Investigation of Receptor and Non-Receptor Tyrosine Kinase Inhibitors for the Treatment of Epithelial Ovarian Cancer

Por Klempner, Samuel J., Myers, Andrea P., Mills, Gordon B., Westin, Shannon N.
Publicado em 2013

Genetic polymorphisms and endometrial cancer risk

Por Meyer, Larissa A, Westin, Shannon N, Lu, Karen H, Milam, Michael R
Publicado no Expert Rev Anticancer Ther (2008)

The rise of genomic profiling in ovarian cancer

Por Previs, Rebecca A., Sood, Anil K., Mills, Gordon B., Westin, Shannon N.
Publicado no Expert Rev Mol Diagn (2016)

Clinically Significant Endometrial Cancer Risk Following a Diagnosis of Complex Atypical Hyperplasia

Por COSTALES, Anthony B., SCHMELER, Kathleen M., BROADDUS, Russell, SOLIMAN, Pamela T., WESTIN, Shannon N., RAMIREZ, Pedro T., FRUMOVITZ, Michael
Publicado no Gynecol Oncol (2014)

Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: a 16-year experience

Por Armbruster, Shannon D., Previs, Rebecca, Soliman, Pamela T., Westin, Shannon N., Fellman, Bryan, Jhingran, Anuja, Fleming, Nicole D.
Publicado no Gynecol Oncol (2019)